|
A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada. |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AbbVie; Amgen; Astellas Pharma; Janssen; Merck; Sanofi |
|
|
Research Funding - Abbott; Janssen; Lidds; Sanofi; TerSera |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb |
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Ipsen; Janssen Oncology; Roche Canada; Tersera |
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Ipsen; Janssen Oncology; Roche Canada; Tersera |